Tethys Bioscience

Tethys Bioscience is a biotechnology firm focused on innovative solutions for healthcare and agriculture, specializing in biopharmaceuticals and agricultural bio-solutions that enhance therapeutic efficacy and crop resilience. Founded in 2002 in Emeryville, US, Tethys Bioscience focuses on developing advanced biotechnological products. The company raised USD 10 mn in Venture Debt financing on July 22, 2010, from Oxford Finance Corporation and Silicon Valley Bank, bringing the total amount raised to USD 23 mn. The company has completed a total of 6 deals, indicating a solid investment strategy.

Tethys Bio specializes in innovative biotechnological solutions designed to address critical challenges in healthcare and agricultural sectors. The company’s core product offerings include advanced biopharmaceuticals aimed at enhancing therapeutic efficacy and cutting-edge agricultural bio-solutions that improve crop resilience and yield. These products function through proprietary mechanisms that involve targeted delivery systems and bioactive compounds, addressing specific health conditions and environmental stressors in crops. Tethys Bio targets a diverse client base, which includes healthcare providers, pharmaceutical companies, and agricultural businesses, primarily operating in North America, Europe, and select markets in Asia.

The company’s commitment to enhancing quality of life and agricultural productivity positions it as a leader in its field. Tethys Bio generates revenue through a structured model that emphasizes partnerships and B2B transactions. The company collaborates with healthcare organizations and agricultural firms to provide tailored solutions, often structured as long-term contracts and subscription services for its biotechnological products. These transactions typically involve recurring payments for ongoing product access and support services.

Among its flagship offerings are proprietary biopharmaceuticals and agricultural solutions, which are available through a tiered pricing strategy that reflects the complexity and scale of client needs. This approach enables Tethys Bio to establish enduring relationships with clients while ensuring a consistent revenue stream from its innovative product lines. Tethys Bioscience plans to leverage the USD 10 mn raised in the latest funding round to accelerate product development and expansion into new markets. The company is currently working on launching new biopharmaceuticals and agricultural solutions aimed at enhancing crop yields and addressing urgent healthcare challenges.

Tethys Bio targets specific expansion into European and select Asian markets by 2015, aiming to broaden its global footprint in both sectors.